Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT04504604
NA

TCF-001 TRACK (Target Rare Cancer Knowledge) Study

Sponsor: TargetCancer Foundation

View on ClinicalTrials.gov

Summary

This open label, non-randomized, multi-center, pragmatic study aims to establish whether patients with rare tumors can benefit from matched molecular therapy as dictated by their next-generation sequencing (NGS) results.

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

400

Start Date

2020-10-01

Completion Date

2025-12

Last Updated

2024-08-09

Healthy Volunteers

No

Interventions

DIAGNOSTIC_TEST

FoundationOne CDx and FoundationOne Liquid CDx

Eligible patients will have Foundation Medicine blood and tissue testing and have their results reviewed by the study's Virtual Molecular Tumor Board which, in turn, will make recommendations for treatment to treating physicians.

Locations (1)

TargetCancer Foundation

Cambridge, Massachusetts, United States